Suriya’s Scene continues its steady run even as the festive weekend fades. Directed by Jithu Madhavan and released on 6 November, the Tamil-Telugu bilingual has now completed five days in theatres and sits at a worldwide gross of ₹174.40 crore. Made on a reported budget of around ₹125 crore, the film has already recovered a substantial portion of its cost and is heading toward the ₹200 crore global mark with healthy momentum.
India remains the core market. After five days the film has collected ₹97.40 crore nett and ₹113.15 crore gross domestically. Overseas contributed another ₹61.25 crore, with roughly ₹6 crore added on Day 5 alone. That international share continues to look strong for a South Indian release this early in its run.
Here’s the day-wise India gross picture so far:
- Day 1 (Friday, 6 Nov): ₹22.25 crore
- Day 2 (Saturday, 7 Nov): ₹23.65 crore
- Day 3 (Sunday, 8 Nov): ₹27.45 crore
- Day 4 (Monday, 9 Nov): ₹24.85 crore
- Day 5 (Tuesday, 10 Nov): ₹14.95 crore
Day 5 brought the expected weekday correction. The film netted ₹12.85 crore across 5,324 shows with overall occupancy around 45%. Average collection per show settled near ₹24,100. The Tamil version carried the bulk of the business (around ₹10.35 crore nett), while the Telugu version added roughly ₹2.50 crore. Tamil Nadu stayed the strongest territory, followed by steady numbers from Andhra-Telangana, Karnataka and Kerala.
Compared with the previous day, collections dropped about 40% a normal Tuesday dip after a strong Diwali weekend that saw daily nett figures hovering between ₹20–23.65 crore. Ticket sales remain healthy overall; the film had already sold more than 62 lakh tickets by the end of Day 4 and continued adding solid footfalls on the fifth day.
Word of mouth is still working in the film’s favour. Audiences have responded well to the mix of action, humour and the performances of Suriya, Nazriya and Naslen. With the India nett total now just under the ₹100 crore mark and worldwide gross past ₹174 crore, Scene looks set for a stable first-week finish and a healthy theatrical run ahead.